Skip to content
Zokinvy(lonafarnib)
Zokinvy (lonafarnib) is a small molecule pharmaceutical. Lonafarnib was first approved as Zokinvy on 2020-11-20. It has been approved in Europe to treat laminopathies and progeria. It is known to target GTPase NRas, GTPase HRas, and GTPase KRas.
Download report
Favorite
FDA Novel Drug Approvals 2020
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
hereditary congenital and neonatal diseases and abnormalitiesD009358
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Zokinvy
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Lonafarnib
Tradename
Company
Number
Date
Products
ZOKINVYEiger BiopharmaceuticalsN-213969 RX2020-11-20
2 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
zokinvyNew Drug Application2021-02-10
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
LONAFARNIB, ZOKINVY, EIGER BIOPHARMS
2027-11-20ODE-324
2025-11-20NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Lonafarnib, Zokinvy, Eiger Biopharms
78385312024-07-26U-3070
88283562023-10-17U-3070
ATC Codes
A: Alimentary tract and metabolism drugs
— A16: Other alimentary tract and metabolism products in atc
— A16A: Other alimentary tract and metabolism products in atc
— A16AX: Various alimentary tract and metabolism products
— A16AX20: Lonafarnib
HCPCS
No data
Clinical
Clinical Trials
35 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic hepatitis dD019701—21——3
Hepatitis delta virusD003698——1——1
Myelodysplastic syndromesD009190D46——1——1
Myelomonocytic leukemia chronicD015477C93.1——1——1
Non-small-cell lung carcinomaD002289——1——1
Neoplasm metastasisD009362EFO_0009708——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5033———5
ProgeriaD011371E34.814——15
Hepatitis dD003699EFO_0007304—3———3
GlioblastomaD005909EFO_000051521———3
Prostatic neoplasmsD011471C6121———2
Lung neoplasmsD008175C34.9021———2
Bcr-abl positive chronic myelogenous leukemiaD015464EFO_000034011———2
Chronic hepatitisD006521K73.9—2———2
Ovarian neoplasmsD010051EFO_0003893C5611———1
Stomach neoplasmsD013274EFO_0003897C1611———1
Show 5 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151792————2
GliosarcomaD0183162————2
Head and neck neoplasmsD0062582————2
Central nervous system neoplasmsD0165432————2
NeoplasmsD009369C802————2
SarcomaD0125091————1
AstrocytomaD001254EFO_00002711————1
Supratentorial neoplasmsD015173C71.01————1
Squamous cell neoplasmsD0183071————1
LymphomaD008223C85.91————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameLONAFARNIB
INNlonafarnib
Description
Lonafarnib is a 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide that has R configuration. It is used as oral farnesyltransferase inhibitor. It has a role as an antineoplastic agent and an EC 2.5.1.58 (protein farnesyltransferase) inhibitor.
Classification
Small molecule
Drug classfarnesyl transferase inhibitor
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
NC(=O)N1CCC(CC(=O)N2CCC([C@H]3c4ncc(Br)cc4CCc4cc(Cl)cc(Br)c43)CC2)CC1
Identifiers
PDB1O5M
CAS-ID193275-84-2
RxCUI—
ChEMBL IDCHEMBL298734
ChEBI ID—
PubChem CID148195
DrugBankDB06448
UNII IDIOW153004F (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
NRAS
NRAS
HRAS
HRAS
KRAS
KRAS
Organism
Homo sapiens
Gene name
NRAS
Gene synonyms
HRAS1
NCBI Gene ID
Protein name
GTPase NRas
Protein synonyms
N-ras protein part 4, neuroblastoma RAS viral (v-ras) oncogene homolog, neuroblastoma RAS viral oncogene homolog, proto-oncogene GTPase, Transforming protein N-Ras, v-ras neuroblastoma RAS viral oncogene homolog
Uniprot ID
Mouse ortholog
Nras (18176)
GTPase NRas (P08556)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,069 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,636 adverse events reported
View more details